PAI Partners and Carlyle have agreed to sell Theramex, the London-based women's health specialty pharmaceutical company, to Cinven. The sale comes around four years after the firms acquired the business. Theramex has undergone a significant transformation over the past four years and is now a stronger, more diversified international business dedicated to women's health.
The company sells treatments for menopause, osteoporosis, contraception, uterine health, and fertility. Its products reach more than six million patients in over 80 countries across Europe, Africa, Asia-Pacific, and Latin America, and it has more than 500 employees. PAI and Carlyle also expanded its commercial infrastructure to 17 direct markets and invested in its operating model, supply chain, and leadership.
Source: PE Insights · Summarized by HeadlinesBriefing